By Karen Roman
ReAlta Life Sciences said it presented new clinical data from its Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AE-COPD) program at the American Thoracic Society 2025 International Conference, taking place on May 18-21, in San Francisco.
The findings show how ReAlta’s peptide RLS-0071 (pegtarazimod) inhibited the migration of neutrophil into the lungs by approximately 50%, it stated.
“We look forward to completing our Phase 2 trial in patients with AE-COPD (NCT06175065) later this year and exploring opportunities for our novel dual-targeting peptide platform to deliver effective new therapies for respiratory diseases,” said Kenji M. Cunnion, MD, MPH, ReAlta’s Chief Medical Officer.
Contact:
